AU2021240417A1 - Forskolin-inducible promoters and hypoxia-inducible promoters - Google Patents

Forskolin-inducible promoters and hypoxia-inducible promoters Download PDF

Info

Publication number
AU2021240417A1
AU2021240417A1 AU2021240417A AU2021240417A AU2021240417A1 AU 2021240417 A1 AU2021240417 A1 AU 2021240417A1 AU 2021240417 A AU2021240417 A AU 2021240417A AU 2021240417 A AU2021240417 A AU 2021240417A AU 2021240417 A1 AU2021240417 A1 AU 2021240417A1
Authority
AU
Australia
Prior art keywords
seq
acgt
tca
tga
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021240417A
Other languages
English (en)
Inventor
Michael L. Roberts
Victoria Fiona TORRANCE
Graham WHYTESIDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AskBio Inc
Original Assignee
AskBio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2005473.0A external-priority patent/GB202005473D0/en
Priority claimed from GBGB2005475.5A external-priority patent/GB202005475D0/en
Priority claimed from GBGB2101969.0A external-priority patent/GB202101969D0/en
Priority claimed from GBGB2101972.4A external-priority patent/GB202101972D0/en
Application filed by AskBio Inc filed Critical AskBio Inc
Publication of AU2021240417A1 publication Critical patent/AU2021240417A1/en
Assigned to AskBio Inc. reassignment AskBio Inc. Amend patent request/document other than specification (104) Assignors: ASKLEPIOS BIOPHARMACEUTICAL, INC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2021240417A 2020-03-26 2021-03-26 Forskolin-inducible promoters and hypoxia-inducible promoters Pending AU2021240417A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063000155P 2020-03-26 2020-03-26
US63/000,155 2020-03-26
US202063010330P 2020-04-15 2020-04-15
GB2005475.5 2020-04-15
GBGB2005473.0A GB202005473D0 (en) 2020-04-15 2020-04-15 Forskolin-inducible promoters
GBGB2005475.5A GB202005475D0 (en) 2020-04-15 2020-04-15 Hypoxia-inducible promoters
GB2005473.0 2020-04-15
US63/010,330 2020-04-15
GB2101972.4 2021-02-12
GBGB2101969.0A GB202101969D0 (en) 2021-02-12 2021-02-12 Hypoxia inducible promoters
GBGB2101972.4A GB202101972D0 (en) 2021-02-12 2021-02-12 Forskolin inducible promoters
GB2101969.0 2021-02-12
PCT/GB2021/050743 WO2021191628A1 (en) 2020-03-26 2021-03-26 Forskolin-inducible promoters and hypoxia-inducible promoters

Publications (1)

Publication Number Publication Date
AU2021240417A1 true AU2021240417A1 (en) 2022-10-20

Family

ID=77890128

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021240417A Pending AU2021240417A1 (en) 2020-03-26 2021-03-26 Forskolin-inducible promoters and hypoxia-inducible promoters

Country Status (7)

Country Link
US (1) US20230374526A1 (cg-RX-API-DMAC7.html)
EP (1) EP4127180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023519925A (cg-RX-API-DMAC7.html)
CN (1) CN115698300A (cg-RX-API-DMAC7.html)
AU (1) AU2021240417A1 (cg-RX-API-DMAC7.html)
CA (1) CA3171636A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021191628A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025015211A1 (en) * 2023-07-12 2025-01-16 Georgia Tech Research Corporation Synthetic genetic constructs that induce gene expression in response to tumor-specific metabolic alterations
WO2025090555A1 (en) * 2023-10-23 2025-05-01 University Of Southern California Ultrasound-controlled car t with sensitive evolved promoter and feedback integration and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
IT1258959B (it) 1992-06-09 1996-03-11 Impianto a moduli mobili per lo sviluppo e la produzione di prodotti biotecnologici su scala pilota
EP1136567A1 (en) * 2000-03-24 2001-09-26 Advanced Array Technologies S.A. Method and kit for the screening, the detection and /or the quantification of transcriptional factors
US7402406B2 (en) * 2001-10-31 2008-07-22 Astellas Pharma Inc. Methods of evaluating phosphatase inhibitors
US20060127371A1 (en) * 2002-11-25 2006-06-15 Peppelenbosch Maikel P ASB transcription repressor proteins and nucleic acids and their application in expansion of stem cells
JP2007520820A (ja) 2004-02-03 2007-07-26 エクセラーエックス, エルエルシー 製造のためのシステムおよび方法
CN101001945B (zh) 2004-06-04 2012-02-08 艾克塞勒雷克斯公司 一次性生物反应器系统及方法
US20080206817A1 (en) 2004-12-07 2008-08-28 Johann Brass Rhamnose Promoter Expression System
US20090305626A1 (en) 2005-12-05 2009-12-10 Hope Ernest G Prevalidated, modular good manufacturing practice-compliant facility
EP2207796A2 (en) * 2007-11-02 2010-07-21 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Polypeptides involved in neuronal regeneration-associated gene expression
US8815779B2 (en) * 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
WO2011139708A2 (en) 2010-04-26 2011-11-10 Toyota Motor Engineering & Manufacturing North America, Inc. Improved hydrogen release from complex metal hydrides by solvation in ionic liquids
US10371394B2 (en) 2010-09-20 2019-08-06 Biologics Modular Llc Mobile, modular cleanroom facility
US9388373B2 (en) 2011-03-08 2016-07-12 University Of Maryland Baltimore County Microscale bioprocessing system and method for protein manufacturing
KR102128957B1 (ko) 2011-10-07 2020-07-02 론자 리미티드 조절가능한 프로모터
MY172311A (en) * 2012-08-02 2019-11-21 Univ Putra Malaysia Hypoxia inducible factor (hif) activity reporter cell line
AU2018215537B2 (en) * 2017-02-03 2023-11-09 Manus Bio, Inc. Metabolic engineering for microbial production of terpenoid products
CN110582574A (zh) * 2017-03-13 2019-12-17 麻省理工学院 合成启动子
CN107523588B (zh) * 2017-08-18 2020-08-07 深圳大学 一种四环素慢病毒诱导表达载体及其建立方法和应用
GB201713545D0 (en) * 2017-08-23 2017-10-04 Synpromics Ltd Expression control using a regulatable intron
WO2021158658A1 (en) * 2020-02-04 2021-08-12 The Board Of Trustees Of The Leland Stanford Junior University Split crispr-cas for biological signal integration

Also Published As

Publication number Publication date
CA3171636A1 (en) 2021-09-30
EP4127180A1 (en) 2023-02-08
CN115698300A (zh) 2023-02-03
JP2023519925A (ja) 2023-05-15
WO2021191628A1 (en) 2021-09-30
US20230374526A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
CN109295053B (zh) 通过诱导剪接位点碱基突变或多聚嘧啶区碱基置换调控rna剪接的方法
JP2023081927A (ja) アデノ随伴ウイルスを生産するための哺乳動物細胞
US12472269B2 (en) Liver-specific inducible promoters and methods of use thereof
JP2023522020A (ja) 顔面肩甲上腕型筋ジストロフィーのためのcrispr阻害
WO2022232442A2 (en) Multiplex crispr/cas9-mediated target gene activation system
US20230374526A1 (en) Forskolin-inducible promoters and hypoxia-inducible promoters
US20250302992A1 (en) Polycistronic Expression of Gut Peptides
US20230167458A1 (en) Forskolin-inducible promoters and hypoxia-inducible promoters
Niessen et al. Novel diabetes mellitus treatment: mature canine insulin production by canine striated muscle through gene therapy
EP4722361A1 (en) Vector used for preparing circular rna and method
RU2834035C1 (ru) Нуклеиновая кислота, содержащая последовательность гена PRDM16, предназначенная для снижения массы тела млекопитающего, экспрессионный вектор для экспрессии в клетках млекопитающего, способ его доставки и способ снижения массы тела млекопитающего
US20260002151A1 (en) Compositions and methods for the modification and regulation of liver gene expression
US20260041789A1 (en) Gene therapy DNA vector based on gene therapy DNA vector GDTT1.8NAS12 carrying the therapeutic gene selected from the group of DDC, IL10, IL13, IFNB1, TNFRSF4, TNFSF10, BCL2, HGF, and IL-2 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain JM110-NAS/GDTT1.8NAS12-DDC, or Escherichia coli strain JM110-NAS/GDTT1.8NAS12-IL10, or Escherichia coli strain JM110-NAS/GDTT1.8NAS12-IL13, or Escherichia coli strain JM110-NAS/GDTT1.
WO2025084955A1 (ru) Нуклеиновая кислота для снижения массы тела млекопитающего
HK40056629A (en) Liver-specific inducible promoters and methods of use thereof
HK40056629B (en) Liver-specific inducible promoters and methods of use thereof
CN121358865A (zh) 肝脏特异性调控核酸序列
US20140031417A1 (en) Skeletal muscle-specific enhancer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ASKBIO INC.

Free format text: FORMER NAME(S): ASKLEPIOS BIOPHARMACEUTICAL, INC.